DELATESTRYL (testosterone enanthate) by Hikma is androgens, including testosterone and dihydrotestosterone (dht) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. First approved in 1953.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
DELATESTRYL (testosterone enanthate) is a long-acting androgen replacement therapy administered via intramuscular injection. It treats male hypogonadism by restoring testosterone levels, addressing deficiencies caused by primary testicular failure or secondary hypothalamic-pituitary dysfunction. The drug works by mimicking natural testosterone to restore secondary sex characteristics and normal male physiological function.
Product is in mature/late-stage lifecycle with legacy status as a 70-year-old approved therapy; team size and investment likely stable or declining.
androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum;…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
Pharmacokinetic Study of Testosterone Enanthate
A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
Worked on DELATESTRYL at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDELATESTRYL at Hikma is a legacy, generic-competitive product in LOE transition with minimal active development. Career impact: roles focus on defending market share against generics and maintaining compliance rather than innovation or expansion.